# 54gene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/54gene

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.54gene.com
- Total disclosed funding: $45M
- Latest round: Series B (Sep 16, 2021)
- Investors on record: 15

## About

54gene Inc. is a US-based biotechnology company specializing in genomic research and diagnostic solutions, striving to improve healthcare outcomes through innovative genetic testing and analysis.Founded in 2019 and headquartered in San Francisco, US, 54gene Inc. operates in the genomic research sector, providing extensive diagnostic solutions. The company has successfully raised funds through four deals, with the latest funding round being a Series B of USD 25.00 mn on September 16, 2021, led by Cathay Capital, with participation from Adjuvant Capital, Endeavor Catalyst, Ingressive Capital, KdT Ventures, and Plexo Capital. CEO Abasi Ene-Obong has been instrumental in the company's growth trajectory.54gene focuses on genomic research and diagnostic solutions, aiming to enhance healthcare outcomes through innovative genetic testing. Their primary offerings include advanced genomic sequencing services, utilized for applications such as disease diagnosis, drug discovery, and personalized medicine. The company serves healthcare institutions, pharmaceutical companies, and research organizations, providing them with essential tools for advancing genetic research and therapeutic development. 54gene markets its products in North America, specific regions in Europe, and emerging markets in Africa, where interest in genetic research is increasing.54gene's revenue model is based on contracts with healthcare providers, research institutions, and pharmaceutical companies for genomic sequencing services. Transactions occur through agreements for specific studies or testing projects, which may involve one-time fees or ongoing partnerships based on a subscription model for access to genomic databases and analytical tools. The company's flagship services include comprehensive genomic analysis and custom research services, with pricing reflecting the complexity of services provided, aligning with industry standards.Following the Series B funding round of USD 25.00 mn in September 2021, 54gene plans to utilize the capital to expand its presence across the African continent. The company is focused on launching new products designed to enhance its genomic service offerings, with specific release dates to be determined as development progresses. Through these initiatives, 54gene aims to tap into new markets and strengthen its position in the evolving landscape of genomic research.

## Funding rounds

- Series B, Sep 16, 2021, $25M — Cathay Capital, Endeavor Catalyst, KdT Ventures, Ingressive Capital, Plexo Capital, Adjuvant Capital
- Series A, Mar 1, 2020, $15M — Y Combinator, Better Ventures, KdT Ventures, V8 Ventures, Aera, Ingressive Capital, Pioneer Fund, Fifty Years, Raba, Adjuvant Capital
- Seed, Jan 1, 2019, $4.5M — Y Combinator, Better Ventures, Techammer, KdT Ventures, Hack VC, Pioneer Fund, Fifty Years

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed, Series A
- Better Ventures — Seed, Series A
- Techammer — Seed
- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Seed, Series A, Series B
- Hack VC (https://capitalatlas.ai/funds/hack-vc) — Seed
- Pioneer Fund (https://capitalatlas.ai/funds/pioneer-fund) — Seed, Series A
- Fifty Years (https://capitalatlas.ai/funds/fifty-years) — Seed, Series A
- V8 Ventures (https://capitalatlas.ai/funds/v8-ventures) — Series A
- Aera (https://capitalatlas.ai/funds/aera) — Series A
- Ingressive Capital (https://capitalatlas.ai/funds/ingressive-capital) — Series A, Series B
- Raba (https://capitalatlas.ai/funds/raba) — Series A
- Adjuvant Capital (https://capitalatlas.ai/funds/adjuvant-capital) — Series A, Series B
- Cathay Capital — Series B
- Endeavor Catalyst (https://capitalatlas.ai/funds/endeavor-catalyst) — Series B
- Plexo Capital (https://capitalatlas.ai/funds/plexo-capital) — Series B